DUNCAN BARBARA GAYLE 4

What Happened

• Barbara Gayle Duncan, a director of Halozyme Therapeutics, received two grant awards on May 5, 2026: 3,796 restricted stock units (RSUs) and a derivative award of 6,040 (stock option) shares. Both grants are reported at $0.00 acquisition price (common for equity awards) and will vest in full on the earlier of May 5, 2027 or the company’s next annual meeting of stockholders.

Key Details

• Transaction date: 2026-05-05; Form 4 filed: 2026-05-07.
• Reported price/value: $0.00 for both the RSUs and the derivative award.
• Vesting: Both awards vest in full on the earlier of (i) May 5, 2027 or (ii) the date of the next annual meeting.
• RSU deferral: The RSUs are subject to a written deferral election under the Issuer’s Directors Deferred Equity Compensation Plan; shares are released upon completion of director service.
• Shares owned after transaction: not specified in the provided filing.
• Filing timeliness: Filing date is two days after the transaction; no late-filing flag noted in the provided data.
• Transaction code: A = Award/Grant. The 6,040-share item is a derivative (option) grant.

Context

• These are compensation grants to a director under the company’s director compensation program, not purchases or sales. Such awards are routine for non-employee directors and represent future economic interest contingent on vesting and service. The option grant is not an exercise; it vests in the future per the schedule above.